is the only leukemia type that has not been related with occupational exposure to radiation.
Some of the ethnic and racial variations could be explained by genetic factors. Familial aggregation of CLL has been reported, with excess in first-degree relatives of CLL ranging from twofold to sevenfold compared with control~.'~,'* An underlying inherited chromosome abnormality (eg, of chromosome 12) or a high frequency of chromatid exchange figures (eg, 14q+) could predispose to CLL,' as well as consanguinity." Few associations with HLA antigen have been identified. The possible effect of chronic infections, connective tissue disorders, or allergic conditions in CLL remains controversial.
CLINICAL AND LABORATORY FINDINGS
Clinical findings in CLL are generally limited to blood lymphocytosis, with or without peripheral lymphadenopathy and/or hepato-splenomegaly. Diagnosis of CLL is more and more often made at an early stage of the di~ease'~-'~; patients with peripheral blood (PB) and marrow lymphocytosis, without organomegaly or cytopenias (Rai's stage 0) accounted for 29% of our 973 patients diagnosed between 1980 and 1985 as compared with 39% of the 1,279 patients diagnosed between 1985 and 1990 .
Although involvement of any other organ system is possible in CLL, including skin,*' gastrointestinal tract," lungs and pleura? central nervous system or peripheral nerves," kidneys:' bone, and salivary and lachrymal glands,29 it is rare, and should be distinguished from infection, adverse effects of treatment, other neoplasia, and progression to a more aggressive lymphoproliferative disorder.
Minimum requirements for a diagnosis of CLL in~l u d e "~' sustained lymphocytosis of greater than 10 x 109/L in PB with mature appearing lymphocytes and bone marrow (BM) lymphocytosis of at least 30% in BM aspirates. In patients with 5 to 10 x 109/L lymphocytes, the permanent nature of the lymphocytosis should be documented, and cell marker studies like CD5 expression by B cells and/or clonal excess of membrane K and A chain are necessary to establish clonality. Although blood lymphocyte counts may be as high as 1,000 x 109/L, about two-thirds of the patients now present with lymphocytes less than 30 x 10y/L. In typical cases of CLL, the cells are small with a narrow rim of cytoplasm, and the nuclear chromatin is dense and nucleoli are not visible. However, in some cases of CLL, morphologic features at diagnosis are different, including (1) a spectrum of small to large lymphocytes with occasional (less than 10%) prolymphocytes and (2) a mixture of small lymphocytes and prolymphocytes ( > 10% and <S5%) designated CLL/PL.36 Those two variants have been described as CLL, mixed cell types.353x
Anemia and thrombopenia are now relatively rarely found at diagnosis and mainly occur during the course of the disease (see below). Four different patterns of lymphoid infiltration are usually recognized on BM biop~ies~',~*: nodular, interstitial, mixed (nodular and interstitial), and diffuse; but sequential studies show that they represent a dynamic process, with progression to diffuse infiltration occurring coincidentally with clinical progre~sion.~'
CLINICAL COURSE
Although very rare cases of spontaneous remission in CLL have been reported" and a significant proportion of patients remain stable for years, the total tumor cell burden in CLL generally tends to expand at a variable speed. The most frequent complications include infection, blood cytopenias, and transformation of the disease.
Infections occur mainly at advanced stages." Susceptibility to infection results mainly from hypogammaglobulinemia, but also from specific antibody deficiency, depleted cell-mediated immunity, neutropenia, and poor opsonization. Infections are mainly bacterial and viral infections (generally due to herpes viruses: herpes simplex or zoster); mycobacterial and fungal infections are less frequent.
Anemia in CLL may result from immune hemolysis (see below), excessive spleen pooling, reduced red blood cell (RBC) production associated to massive BM infiltration, or pure RBC aplasia, of probable immune origin.41 Those mechanisms, however, may be associated. Thrombopenia may also result from decreased platelet production by infiltrated BM and/or by platelet destruction by platelet autoantibodies4' or excessive spleen pooling in cases with prominent splenomegaly. Immune neutropenia is rarely seen and is a feature of T-rather than B-CLL. 43 In a small proportion of cases, CLL may evolve to more aggressive forms, mainly by development of diffuse large cell lymphoma (Richter's syndrome).44 Richter's syndrome, which develops in 3% to 10% of CLL is heralded by sudden onset of general symptoms or a rapidly progressive tumor mass whose biopsy shows large cell immunoblastic lymphoma along with evidence of CLL in sites not involved by lymphoma. Response to chemotherapy is generally poor, and median survival is only 4 months. Other types of transformation include: (1) " prolymphocytoid" transformation, with growing numbers of prolymphocytes in blood samples, and increasing tumor mass, cytopenias, and resistance to treatment4' (It remains uncertain, however, whether this entity differs or not from CLL/PL.36); (2) acute lymphoblastic leukemia (ALL), of which only a few cases have been clearly documented," and which has to be distinguished from exceptional cases of acute myeloid leukemia (AML), in patients who had generally received prolonged treatment with alkylating agents; and (3) myeloma, which is also exceptional in CLL.47 Whether Richter's syndrome and other transformations represent clonal evolution of CLL or are independent disorders remains controver~ia1.~~ Finally, CLL patients seem to have an increased risk of nonhematologic neoplasms as compared with control patients or patients with other malignancies.29As However, The French Cooperative Group on CLL (FCG on CLL) recently reported that the increase in epithelial tumors was mainly found in patients who had received long-term continuous chlorambucil? and it is uncertain whether untreated patients also have an increased risk of other neoplasms.
DIFFERENTIAL DIAGNOSIS
CLL is generally easy to distinguish from reactive lymphocytosis. The following mature B-cell malignancies should be distinguished from B-CLL on the basis of cytology and membrane phenotype: (1) B-prolymphocytic leukemia (PLL):' characterized by extreme leukocytosis ( > 100 x 10' /L) and splenomegaly, with minimal or no lymphadenopathy. The prolymphocyte is the predominant cell in PB ( > SS%, usually > 70%) and is characterized by its large size, prominent nucleolus, and lower nuc1ear:cytoplasmic ratio than the small CLL lymphocyte. The membrane phenotype is different from that of CLL, including increased expression of surface Igs, low mouse rosette formation, low CDS expression, and positivity for FMC7. As seen above, however, CLL/PL has features intermediate with those of classic CLL and classic PL, and includes patients with typical CLL that evolves into "prolymphocytoid" transformation, as well as patients with an increased proportion of prolymphocytes at diagnosis. Hodgkin's lymphoma ("lymphosarcoma cell leukemia"), generally of follicular or diffuse small cleaved cell histol~g y .~~~' Typical cells are often pleomorphic with nuclear clefting. The disease can also be distinguished from CLL by lymph node biopsy, histologic BM pattern, and immunologic features (strong surface Igs, low percentage of mouse rosettes, positivity of FMC7 and, often, of CD10, negativity of CDS). (5) Waldenstrom's macroglobulinemia, in cases where circulating lymphocytosis is present. The malignant lymphocytes generally have plasmacytoid features, however, and secrete substantial monoclonal IgM in the serum.
B-CLL should also be differentiated from mature T-cell disorders, which are far less frequent than mature B-cell disorders, at least in Western countries, and have been classified into four main types, including T-CLL (or large granular lymphocyte leukemia), T prolymphocytic leuke- 
Clinical Staging Systems
Although some prognostic factors, including sex, age, peripheral lymphocytosis, lymph node and spleen enlargement, anemia, and thrombopenia, had been reported for some time in CLL, the specific importance of each of these factors remained uncertain until the staging proposals of Rai et Recently, Rai et a1 suggested that there were essentially three rather than five groups that differed with respect to survival: stage 0 (goQd prognosis), stages I and 11 (intermediate prognosis), and stages I11 and IV (poor prognosis).
The large number of groups in Rai's system and the availability of new statistical methods such as the Cox model led Binet et a12' to define a new staging system in 1981 that includes three groups: stage A, with less than three areas involved (areas include the cervical, axillary, and inguinal lymph nodes, whether unilateral or bilateral spleen and liver), Hb 2 10 g/dL, and platelets 2 100 x lo9& stage B, with at least three areas involved, Hb 2 10 g/dL, and platelets 2100 x loy& and stage C, Hb less than 10 g/dL or platelets less than 100 x 10y/L or both (independently of the areas involved). The validity of this system was confirmed in six retrospective series and in a prospective series of 973 cases."
Comparison of both systems in French series shows that Rai's good prognosis group (stage 0) includes 30% of all patients with a 7-year survival of 76%, whereas Binet's good prognosis group (stage A) includes 63% of CLL patients, with a 7-year survival of 67%.27 Two-thirds of Rai 
Other Prognostic Factors
Three parameters have shown independent prognostic value in CLL in addition to clinical staging: rapid lymphocyte count doubling time (less than 12 months) is associated with short survivalz6; a diffuse pattern of infiltration carries a poor prognosis, whereas all others (ie, nondiffuse) patterns give a better ~urvival~~.~*; and patients with a normal karyotype fare better than those with an abnormal one.55-57 Among the latter, patients with single abnormalities have longer survival than patients with complex karyotypes. Although, some reports suggested that trisomy 12, when isolated, did not carry a poor prognosis,55 a cooperative study on 433 cases of CLL found, on the contrary, a shorter survival in patients with trisomy 12, even when isolated.56 In this study, patients with single abnormalities involving chromosome 14q also had shorter survival than those with single aberrations of chromosome 13q and, possibly, 6q, who had the same survival as those with a normal karyoIncreasing age is associated with shorter survival, although the difference loses part of its significance when non-CLL deaths are removed. A higher incidence of more aggressive forms (stages B and C ) has even been found in younger patients in some series" and in our experience (unpublished). Shorter survival is also seen in males, even after excluding non-CLL deaths." Circulating lymphocyte coupt is correlated with survival and threshold values of 30 to 60 x 109/L help identify good and poor prognostic s~b g r o u p s .~~~*~ The prognostic value of other prognostic factors, including surface Ig isotype,S8 low serum Ig levels? high serum deoxythymidine kinase levels,@' high serum levels of soluble CD23,6' and high CR2/CR1 complement receptors, remains
Smouldering CLL
Both Rai's and Binet's staging systems are limited in that they are unable to distinguish patients in the low-risk group who will have an indolent course and good prognosis from a small fraction who will progress. Some of the prognostic variables described above, in addition to threshold values for certain clinical and hematologic parameters, may be useful in such a situation.
Montserrat et alZ6 recently showed that Binet's stage A patients with a lymphocyte count of less than 30 x lO'/L, a lymphocyte doubling time of greater than 12 months, Hb greater than 13 g/dL, and nondiffuse BM histology were very unlikely to progress and had a life expectancy that was not different from that of the sex-and age-matched population. They suggested that these patients should be termed "smouldering" CLL. After 3 years, only 5% of these The progression rate at 5 years was 25% and 54%, respectively, in stages A' and A . Most other groups have confirmed the prognostic value of Hb, lymphocyte count, lymphocyte doubling time, and BM pattern in survival and/or disease progression in patients with Binet's stage A." Progression from stage A was correlated with Rai substaging in at least two studies, and with the presence of a complex caryotype in the Bournemouth A group of 20 patients with Rai stage 0, normal karyotype, and stable disease for 6.5 to 24 years had also been previously reported, and was designated as having "benign monoclonal B-cell lymphocytosis." 66 Although the choice between competing proposals remains somewhat arbitrary, a definition of smouldering CLL appears feasible. Whatever definition is used, survival rates of patients with smouldering CLL are similar to those of the general population. However, a small proportion (about 10%) of them will progress to stage C within 5 years63 and criteria are not currently available to initially detect them. Widespread use of BM biopsy, cytogenetic analysis, and other biologic studies may help to more precisely define smouldering CLL. Most cases of B-CLL appear to react with CD19, CD20, CD24, CD37, and CD21 monoclonal antibodies (MoAbs).*" About 60% of CLL are positive for CD23,6' whereas membrane positivity with CD22 is infrequent." CLL B cells and HCL B cells have been found to express a 69-Kd glycoprotein that is not expressed by normal blood T and B lymphocytes, thymocyte-cultured T-and B-cell lymphoblastoid cell lines, or acute lymphoblastic leukemia cells." In contrast to B-cell prolymphocytic leukemia, which constantly binds the FMC7 antibody, the reactivity of CLL B cells is not CALLA (CD10) is almost constantly negative, whereas reactivities with subepitopes of CD18"85 and CDll,% as well as with CD6, CD7, and the TQ1 antigen, have been reported in some cases of B-CLL. 87 Interestingly, myelomonocytic antigens have also been found to be expressed by CLL B Contrary to most other B-cell malignancies, CLL B lymphocytes are characterized by three particular phenotypic patterns: (1) B-CLL lymphocytes almost always express low amounts of SmIg,7""y~w although increased amounts of intracytoplasmic Ig have been observed7'; (2) of CLL-B lymphocytes, 31% to 95% frequently form rosettes with mouse erythrocytesy1~'2; and (3) in most cases, they express the CD5 antigenY3 ' 5 a 67-Kd antigenic determinant initially described as a pan-T-cell marker. The normal counterpart of the CD5 B cells that proliferate in CLL was initially found by Caligaris-Capio et al. 96 Furthermore, a substantial number of B cells in 20-week-old fetal lymph nodesy7 and spleen'' express the CD5 marker as well as and 6 chains on their membrane. These fetal cells also appeared to share lectin nonresponsiveness and the inability to cap SIg with CLL B lymphocytes, supporting the idea that they were normal counterparts of B-CLL lymphocytes.% With the advent of double-labeling cytofluorometry techniques, it is presently clear that about 15% of normal B cells express CD5 markers.'" Morphologically, CLL B lymphocytes resemble small resting B cells. However, during recent years, considerable evidence has accumulated indicating that CLL B cells frequently express activation antigens such as CD23,61 CD25, B5, and blast 1, whereas BB1 and CD71 are rarely observed.72 lo ' A high prevalence of CD5 cells during early ontogeny led some investigators to assume that the CD5' CLL B lymphocyte corresponds to expansion of an immature B-cell clone arrested at an immature stage between pre-B and mature B However, this hypothesis does not provide a satisfactory explanation for the difficulty of B-cell differentiation pathways to integrate CD5 antigen expression, not for the high frequency of hypogammaglobulinemia and autoimmunity directed against blood cell components in B-CLL.'"3,1"4 The latter phenomena are only rarely observed in other B-cell neoplasias. Alternatively, it has been postulated that CD5 B cells could correspond to a separate B-cell lineage. There is some evidence indicating that Lyl B cell^,'"^^^^^ the murine counterpart of human CD5 B cells, constitute a discrete B-cell subset. This evidence results from experiments on lethally irradiated mice and from the observation of different behaviors in long-term cultures.'" However, no definitive evidence indicating that CD5' B cells constitute a different B-cell lineage is presently available.
BIOLOGY OF B-CLL

Phenotypic Characteristics of CLL B Lymphocytes
B-Cell Differentiation, Antibody Activity, and Gene Expression
Although earlier studies postulated that B-CLL lymphocytes were frozen at an early stage of differentiation, considerable evidence has accumulated that these cells are able to differentiate. Stevenson et al,lo7 using antiidiotypic reagents. have shown that the pentameric form of SmIg was In a recent work, Kipps et allzo found that a high proportion of B-CLL cells expressing K at the membrane reacted with a murine antiidiotypic antibody raised against a monoclonal IgM rheumatoid factor expressing the Wa idiotype (major cross-reactive idiotype expressed by cryoglobulins). Analysis of K light chain variable region genes expressed by leukemic cells from different patients sharing the Wa idiotype enabled these investigators to show that they all used the unmutated germinal Hum Kv 325 gene.'" Similar restriction was found when VH genes were analyzed.'" These results confirm that CD5+ B-CLL lymphocytes are frequently committed to the production of natural autoantibodies. Furthermore, results from Kipps et a1'20.121 strongly suggest the use of a restricted set of genes by CLL B lymphocyte^"^"' and this was confirmed by the high frequency of natural autoantibody activity found among CLL B lymphocyte^."^^"' Because CD5-B lymphocytes from follicular non-Hodgkin's lymphomas have also been found to be frequently committed to secretion of natural autoantibodies, these results appear to indicate that the autoreactive B-cell repertoire is frequently involved in malignant transformation."*
T and Natural Killer (NK) Cells in B-CLL
In B-CLL, a significant increase in T and NK cells has been found in untreated patient^."^ '" Decreased T-helper cells, increased T-cytotoxic/suppressor cells, and inversion of the T4/T8 ratio have been r e p~r t e d . '~~~' " Decreased helper T-cell function has been frequently rep~rted,'~' whereas some studies suggested increased suppressor function.'*' The expansion of these cells is probably polyclonal in nature, as indicated by the lack of chromosome abnormalities and heterozygosity for glucose 6-phosphate dehydrogenase.129. 130 The reason for this polyclonal expansion of T and NK cells in B-CLL is unknown. However, a recent work claimed that 25% of B-CLL displayed clonal rearrangements of the T-cell receptor p from T cells."' Whether these unexpected results favor the idea that in some cases the CLL target cell could correspond to a stem cell with both B-and T-cell differentiation ability and in some cases with myeloid differentiation potentialities" (as attested by occasional expression of these markers) is as yet unclear. Functional studies of T cells from B-CLL patients indicate that mitogenic responses to phytohemagglutinin (PHA) are usually but not always normal, whereas reactivity to autologous or allogeneic B cells is impaired.lZ6 Data concerning helper, suppressive, NK, and ADCC function are contradictory and difficult to interpret.'03~'".'26
Hypogammaglobulinemia in B-CLL
Hypogammaglobulinemia occurs in 10% to 60% of B-CLL cases, depending on the values used as the lower limit.'" Patients with early forms of the disease tend to have defective specific antibody responses to infection or immuni~ation."'~~ Hypogammaglobulinemia is probably a consequence of accumulation of these individual defects. The pathogenesis of hypogammaglobulinemia in B-CLL is poorly understood, because this phenomenon is rare in other B-cell malignancies including ALL, nodular and diffuse lymphomas, HCL, and prolymphocytic leukemia,'" although it is common in multiple myeloma.
Although regulatory abnormalities in T cells may play a role in the induction of hypogammaglobulinemia, data concerning helper, suppressive, NK, and ADCC are contradictory, and fail to firmly establish their contribution to the development of hypogammaglobu1inemia.l" Based on the information presently available, it appears logical to assume that hypogammaglobulinemia in B-CLL is probably the result of dysfunction of nonclonal B cells. Thus, hypogammaglobulinemia in B-CLL could be a consequence of progressive dilution or inhibition of normal CD5-B cells. This decrease and/or inhibition of normal CD5-B cells could also explain the classical inability of B-CLL to respond to new antigenic challenges, because Lyl B cells (the murine counterpart of human CD5 B cells) have been claimed to be unable to respond to exogenous antigen^."^^'^^ A prominent monoclonal Ig peak, usually of the IgM type, is found in 5% of CLL. With high-resolution agarose gel electrophoresis and immunohation, however, a small amount of a monoclonal component can be identified in the serum or urine of 60% of patient^.'^'
Autoimmune Phenomena in B-CLL
Autoimmune-associated phenomena are frequently observed in B-CLL. These autotoxic manifestations are mainly (CLL 1980 and , positive Coombs test was found at diagnosis in only 1.0%. This lower prevalence is explained probably by the fact that the FCG series included higher numbers of initial forms than previous series. Nevertheless, autoimmune hemolytic anemia occurs in 10% to 25% of patients at some time during the course of the disease. Although Feizi et described one case of cold agglutinin disease in which autoantibodies were the product of CLL B cells, in most cases autoantibodies against RBCs are warm reactive polyclonal IgG and display activity against monomorphic antigens of the rhesus system.'26 Immune thrombocytopenia is observed in about 2% of cases, but higher frequencies of increased platelet associated Igs have been r e p~r t e d .~' . '~~ Pure RBC aplasia and autoantibodies against neutrophils are only rarely observed and there is conflicting evidence concerning the frequency of other aut~antibodies.'~~ This pattern is similar to that observed in primary immunodeficiency syndromes, in which immune thrombocytopenia, autoimmune hemdytic anemia, and pure RBC aplasia are frequently observed.'" Because in B-CLL autoantibodies in most cases are not secreted by the malignant clone, it can be postulated that hypogammaglobulinemia could induce a disturbance in the idiotypic network, in such a way that anti-idiotypic antibodies designed to antagonize autoimmune clones are not made.'" Recently, Sultan et succeeded in suppressing production of anti-VI11 autoaqtibodies by injecting intravenous Ig and speculated that anti-idiotypic suppression mediated by injected Igs could occur. However, no conclusive evidence concerning the role of intravenous Ig in the treatment of autoimmuneassociated phenomena in B-CLL have been reported so far.
Chromosomes and Oncogenes
In recent years, the use of mitogens, such as Epstein-Barr virus, phorbol esters, LPS, and pokeweed, has made it possible to obtain sufficient metaphases for analysis in most cases of CLL. In more than 50% of patients, chromosomal abnormalities are detected. The most frequent abnormality in B-CLL, found in one-third of the abnormal cases, is trisomy 12.s5"73139 In a large cooperative the most frequent structural aberration (51 of 433) affected the 13q14 band, in which the retinoblastoma tumor suppressor gene has been mapped. 14q 32 band rearrangements were found in 41 patients. Less frequently, alterations of chromosomes 11, 6, 18, 3, 17, 7, and 8 were o b s e~v e d .~~
In most cases, chromosomal abnormalities remained unchanged throughout the di~ease.'~ However, this absence of clonal evolution during progression of the disease will have to be confirmed, because it is in contrast with what is observed in other chronic hematologic malignancies (especially, chronic myeloid leukemia or myelodysplastic syndromes).
Little data on a role for proto-oncogene activation in the pathogenesis of CLL are currently available. Most protooncogenes have been found to be normally expressed in B-CLL.la However, Oscier et a1 recently found a deletion of the retinoblastoma gene in several patients with B-CLL and a rearrangement involving band 13q 44.14' A recent study of 32 CLL patients showed bcl-2 rear!angements in three patients, resulting from the juxtaposition of bcl-2 and one of the Ig light chain genes.'" In all cases analyzed, the breakpoints were observed at the 5' flanking region of the bcl-2 gene, and did not invalve the major or pinor breakpoint cluster region typical of the t(14:18) chromosomal translocation observed in follicular lymphomas.'" 144 Rare cases of CLL with (11:14) (q13:q32) translocation involving the J region of the Ig heavy chain and a putative protooncogene (bcl-1) located on chromosome 11 have been re-~0 r t e d . l~~ However, this translocation is more frequently observed in lymphocytic lymphoma of intermediate differe n t i a t i~n '~~'~~ and in some cases of B-PLLL4* than in true B-CLL.'46 Finally, a 1+19 translocation ipvolving the class switch region genes of the a-heavy chain constant region and a putative proto-oncogene located on chromosome 19 (bcl-3) has alsq been r e p~r t e d . '~~~' '~ Those rearrangements, however, which affected the Ig heavy and light chain genes, were observed in a minority of CLL.
THERAPY IN CLL
The variable course of CLL, the advanced age of most of the patients, and the absence of uniform response criteria have constituted important setbacks in the therapy. Thus, an analysis of therapeutic results obtained before the advent of staging systems was almost impossible. Stage A patients, Rai's stage 0 patients, and Rai's I and I1 allocated into Binet's stage A (because their prognosis is close to that of Rai's stage 0) should not be treated unless they progress. On the contrary, there is a general agreement that stage B and C patients should be treated.33334 With the aim of standardizing the response criteria to treatment, the IWCLL and the National Cancer Institute (NCI) Sponsored Working Group defined complete remission (CR), partial response (PR), stable disease (SD), and progressive disease (PD), as shown in Table  In fact, all of these criteria define clinical remission rather than CR, which seems very difficult to obtain. Furthermore, assessment of CR is difficult to make with current therapeutic approaches. More sensitive methods are required to detect residual malignant cells. Flow cytometry with the simultaneous use of CD5 and CD19 or CD20 markers, ~h clonal excess, and analysis of gene rearrangements by the polymerase chain reaction are under study in this setting."'
Single-Agent Chemotherapy
Chlorambucil (CLB) remains the mast commonly used drug in CLL. It is used in a daily oral schedule, intermittent schedule, alone, or associated with coyticosteroids. Response rates have varied from 27% to loo%, but the interpretation of these data is difficult because of the lack of homogeneity in the groups of patients.'53 The first randomized trial in which patients were selected according to clinical stage failed to observe any significant differences in survival between prednisone (PRD), daily CLB + PRD, and intermittent high dose of CLB + PRD.Is6 In the CLL80 protocol, the FCG on CLL analyzed 612 stage A patients randomized between no treatment and daily CLB.4y Although CLB succeeded in slowing down disease progression and favoring remission, the survival rate in the group treated by CLB was significantly shorter when compared with the other group (P < .05, unpublished updated results). These results were explained by the appearance of an excess of epithelial cancers in the CLB group and the poor prognosis of patients evolving to stages B and C under CLB. After this trial, the FCG tested (in the CLL85 Other single agents used in CLL include mainly PRD, busulfan, or cyclophosphamide. Results were often comparable with those observed with CLB alone, though sometimes with more t0xi~ity.l~~ '"
Combination Chemotherapy
In advanced forms of the disease, multiple drug regimens have been proposed. The first was COP (cyclophosphamide, vincristine, and prednisone),'SS which gave a response rate of about 70% but failed to show any benefit over CLB alone or CLB + PRD in three randomized 
Radiotherapy
Radiotherapy, administered either as P32,'74 total body irradiati~n,'~' extracorporal irradiation of blood,176 or thymic irradiati~n,'~~ was found to be effective in a few patients, but severe myelosuppression is a frequent sequel to this treatment. Splenic irradiation has been more often used, mainly in patients with massive splenomegaly when splenectomy was difficult and the patient had associated autoimmune cytopenias. Recently, the UK Medical Research Council observed a better survival for patients treated by splenic irradiation as compared with CLB or CLB + PRD in two randomized trials, but this difference was not ~ignificant.'~.'~~ Finally, irradiation of large lymph nodes may be used in patients resistant to chemotherapy.
Splenectomy
The main indications for splenectomy are autoimmune hemolytic anemia or thrombocytopenia and massive painful splenomegaly. Although several groups have reported that splenectomy may be an efficient treatment in other groups of this has not been shown in randomized studies.
Biologic Response Modifiers
CLL response to antibodies, mainly with CD5 specificity, alone or associated to ricin or an isotope, was recently reviewed, showing only transient efficacy in some patients.'82-'84 Although it is effective in vitro"' in CLL, IFNa has showed a low response rate in vivo except in early stages of the disease.'86-188 Its use once response has been achieved For personal use only. on September 14, 2017 . by guest www.bloodjournal.org From with chemotherapy needs to be investigated. Moderate responses to IL-2 were observed in 7 of 13 patients resistant to chemotherapy; after IL-2, two of those patients receiving chemotherapy had a dramatic response.189 IL-4, in vitro, has an antiproliferative effect on lymphocytes from B-CLL patients; its efficacy is being currently tested in vivo.'9o Lastly, Tura et a1 reported prompt remission with cyclosporin A in three cases of CLL-associated pure RBC aplasia.'"
New Drugs
Fludarabine monophosphate is a fluorinated analogue of adenine that is resistant to deamination by adenosine deaminase. Grever et al were the first to report the efficacy of this drug in CLL.19' Keating et a11y33'94 administered fludarabine 25 or 30 mg/m2/d for 5 days at four weekly intervals to 68 previously treated CLL patients; the response rate was 57% (29% CR and 28% PR). Toxicity was mild and median survival significantly differed between responders and nonresponders. Of 36 previously untreated patients, 75% reached CR. No significantly different results were obtained with fludarabine alone and its combination with corti~osteroids.'~~"~~ A randomized trial comparing fludarabine with CHOP has recently begun in Europe for stage B and C patients.
A total of 110 patients with advanced diseases and often resistant to chemotherapy were treated by pentostatin (2-deoxycoformycine). The response rate was 25%.195 This drug is effective but induces a prolonged decrease in T cells, with a possible increase in the risk of infections.Iy6 2'-chlorodeoxyadenosine has recently been used in refractory CLL patients with a response rate of 53%.19' The period of T-lymphocyte depression after treatment may be shorter than that induced by p e n t~s t a t i n . '~~
Allogeneic BM Transplantation (BMT)
A recent study from the European Group for BMT reported 20 patients with advanced disease who received allogeneic BMT'9Y (M. Michallet, personal communication, June 1991). Their mean age was 40 years and the conditioning regimen always included total body irradiation. One early death and one early graft failure were observed. The remaining 18 patients all developed acute graft-versus-host disease (GVHD). All entered CR. Seven of them died, three from GVHD, one from hemorrhage, one from late graft failure, and two from relapse (at 7 and 54 months, respectively). Ten patients were alive in CR with a mean of follow-up of 30 months.
Intravenous Zgs
The fact that hypogammaglobulinemia was the major cause of the increased risk of sepsis in CLL prompted the use of intravenous Igs to prevent infection. In a doubleblind randomized study, intravenous Igs (400 mg/kg body weight administered every 3 weeks) reduced the incidence of bacterial infections by 50%.200 However, the number of severe bacterial infections and viral infections was unaffected and survival was not modified. In addition, because intravenous Igs are an expensive treatment, their role in preventing infection in routine practice in CLL will have to be better defined.
FUTURE DIRECTIONS
The first question facing epidemiologists and hepatologists is why there is such a low incidence of CLL among Asians. No simple explanation in terms of HLA and other markers is presently available.
Immunologic markers have identified the proliferating lymphocyte in CLL as a mature B lymphocyte that expresses the CD5 marker. It has been postulated that Lyl B cells (the murine counterpart of human CD5' B cells) constitute a separate B-cell lineage. Whether the CD5 marker defines a discrete lineage or is a maturation marker is one of the main issues that may be solved in the near future. Another recent advance was the discovery that the CLL B lymphocyte is in an activated state and can be induced to differentiate. Using B-cell mitogens and somatic hybridization, it was shown that the CLL B lymphocyte is frequently involved in the production of natural autoantibodies and expresses a restricted set of genes. These results may provide a basis for passive immunotherapy with antiidiotypic antibodies. Several recurrent clonal abnormalities, some associated with prognosis, have been found in about 50% of CLL patients, but none of them is specific for CLL, and no consistent abnormalities at the molecular biologic level have been reported. Although Rai's and Binet's clinical systems succeeded in predicting the evolution in most patients, about 20% of low-risk patients will progress to more advanced disease, and those staging systems are presently unable to predict these evolutions. Predicting progression of low-risk patients will be especially important, because more and more CLL are diagnosed at an early stage. Recent findings suggest that BM histology, lymphocyte doubling time, karyotypic studies, and other biologic parameters will help better define patients who will subsequently progress.
In stage A, it appears reasonable to defer any therapy until disease progression is observed. By contrast, there is general agreement that stages B and C should be treated. Intermittent schedules including chlorambucil and prednisone and intermittent CHOP chemotherapy are the most frequently used regimens. New drpgs, especially fludarabin, are promising. The association of these drugs with chlorambucil, doxorubicin, and prednisone is also under study. The role, if any, of biologic response modifiers such as IFNs, IL-2, and MoAbs still has to be defined. Allogeneic BMT gives promising results, but will remain a therapy of exception.
As increasing numbers of complete remissions have now been reported in CLL treated with intensive chemotherapy, autologous BMT using BM harvested in CR is beginning to be investigated in young patients with advanced disease. However, the reality of CR achievement in CLLwill have to be substantiated, especially with immunophenotyping and molecular biology techniques. The benefit of achieving CR in terms of survival will also have to be shown. 
